Document is current
Any future updates will be listed below
-
Authors
Antoniolli, Martina https://orcid.org/0000-0003-2720-9886
Solovey, Maria
Hildebrand, Johannes Adrian https://orcid.org/0000-0002-5451-8038
Freyholdt, Tabea
Strobl, Carolin Dorothea
Bararia, Deepak
Keay, William David
Adolph, Louisa https://orcid.org/0009-0006-4308-2423
Heide, Michael
Passerini, Verena
Winter, Lis
Wange, Lucas https://orcid.org/0000-0002-3275-9156
Enard, Wolfgang
Thieme, Susanne
Blum, Helmut https://orcid.org/0000-0002-3994-2332
Rudelius, Martina
Mergner, Julia https://orcid.org/0000-0002-4332-1280
Ludwig, Christina
Bultmann, Sebastian
Schmidt-Supprian, Marc https://orcid.org/0000-0002-8543-6166
Leonhardt, Heinrich
Subklewe, Marion https://orcid.org/0000-0001-9154-9469
von Bergwelt-Baildon, Michael
Colomé-Tatché, Maria https://orcid.org/0000-0002-2224-7560
Weigert, Oliver https://orcid.org/0000-0002-0987-7373
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (DFG 278529602 - SFB1243 (A11, A12))
Deutsche Forschungsgemeinschaft (WE 4679/2-1)
Deutsche Forschungsgemeinschaft (DFG 278529602 - SFB1243 (A14))
Deutsche Forschungsgemeinschaft (DFG 278529602 - SFB1243 (A14))
Deutsche Forschungsgemeinschaft (WE 4679/2-1)
Deutsche Forschungsgemeinschaft (DFG 278529602 - SFB1243 (A01))
Deutsche Forschungsgemeinschaft (DFG 278529602 - SFB 1243 (A10))
Deutsche Forschungsgemeinschaft (2018.087.1)
Deutsche Forschungsgemeinschaft (SFB 338/1 2021 – 452881907)
Deutsche Forschungsgemeinschaft (SFB 338/1 2021 – 451580403)
Wilhelm Sander-Stiftung (2022.093.1)
Else Kröner-Fresenius-Stiftung (2021_EKES.13)
Lymphoma Research Foundation
Impuls-und Vernetzungsfonds of the Helmholtz-Gemeinschaft
Munich Medical & Clinician Scientist Program
Else Kröner Fresenius Clinican Scientist Program
Cyliax foundation
- License Information
-
More Information
Article History
Received: 21 July 2023
Revised: 29 November 2024
Accepted: 14 January 2025
First Online: 23 January 2025
Competing interests
: MSub receives industry research support from Amgen, BMS/Celgene, Gilead, Janssen, Miltenyi Biotec, Morphosys, Novartis, Roche, Seattle Genetics and Takeda; she serves as a consultant/advisor to AvenCell, CDR-Life, Ichnos Sciences, Incyte Biosciences, Janssen, Miltenyi Biotec, Molecular Partners, Novartis, Pfizer and Takeda and serves on the speakers’ bureau at Amgen, AstraZeneca, BMS/Celgene, Gilead, GSK, Janssen, Novartis, Pfizer, Roche and Takeda. OW receives industry research support from Roche and Incyte; he serves as a consultant/advisor to Beigene, Roche, Incyte and Epizyme. All other authors declare no relevant competing interests.
: The research was conducted in compliance with the relevant guidelines and regulations, as outlined in the Guidelines for Safeguarding Good Research Practice, Code of Conduct (German Research Foundation, revised version 1.1). Informed consent was obtained from all patients participating in clinical trials, including consent for the use of biopsy material for research purposes as previously described [, ]. Approval for molecular analyzes on human material was obtained from institutional and local ethics committees (LMU #223-14, LMU #276-14, LMU #056/00, and LMU #539-15 fed).
